Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.

By Changtao Jiang, Cen Xie, Fei Li, Limin Zhang, Robert G. Nichols, K. Krausz, Jingwei Cai, Yunpeng Qi, Zhong-Ze Fang, Shogo Takahashi and 6 more. Journal of Clinical Investigation, 2015

604 citations recorded by the source corpus.

Subfields: Epidemiology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/d51aa0dbc904f280ca398d130ff660af5aeee85b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. G. Svegliati-Baroni
2. F. Marra

In Molecular Biology

1. G. Svegliati-Baroni
2. W. Tang
3. Stanley L Hazen
4. F. Marra
5. M. Schoeler
6. Robert Caesar
7. T. Kitai

Citations in the corpus

• Gut Microbiota in Cardiovascular Health and Disease (2017, background): “Thus, the capacity to metabolize TβMCA has been associated with microbiota links to obesity and insulin resistance.(113,114) BAs have also been described to affect the cecal microbiota composition of rats, and a direct antimicrobial effect of BAs has been described in vitro.”
• Lipotoxicity and the gut-liver axis in NASH pathogenesis. (2018, background): “Experimental models of NAFLD revealed that obesemicrobiota led to lower level of T-MCAs and higher activity of FXR, inducing synthesis of ceramides that, as soon as reaches the liver, alters lipid metabolism, leading to FAs accumulation [159, 160].”
• Dietary lipids, gut microbiota and lipid metabolism (2019, background): “Several studies indicate that inhibition of intestinal FXR improves metabolic phenotypes [75, 77] but the underlying mechanisms are still unknown.”